DRD2 and central nervous system cancer: Although data on ONC206 concentrations in H3 K27M gliomas are currently the subject of investigation within a Phase I trial,9 oral ONC206 doses of 50–150 mg have been shown to result in peak plasma concentrations of ~0.5–1.5 μM.10 Given that ONC206 penetrates the blood–brain barrier, this may support the notion that D2R antagonism contributes to ONC206 cytotoxicity, in addition to other mechanisms such as Clp protease activation.